Lisocabtagene maraleucel

利基迈仑赛

Report date: 2026/05/21 20:00:22

Base Information

Drug NameLisocabtagene maraleucel
Drug Alias Nameanti-CD19/EGFRt/4-1BB/zeta modified CAR CD8+ and CD4+ T lymphocyte therapyanti-CD19-EGFRt-4-1BB-zeta modified CAR CD8+ and CD4+ T lymphocyte therapy4-1BB-modified CAR CD8+ and CD4+ T lymphocyte therapyGene modified autologous T cellsLisocabtagene maraleucel (Celgene/Juno Therapeutics) +[14] 
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacementsImmunologic cytotoxicity
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaImmunoproliferative DisordersImmune System Diseases +[16] 
Global Approved IndicationsMediastinal NeoplasmsLymphoma, FollicularLymphoma, Large B-Cell, Diffuse
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2021/02/05
Country/TerritoryBelgiumCanadaUnited States +[15] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesJuno Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb SrlcompanyCelgene CorpBristol-Myers Squibb Pharma Eeig +[5] 
Inactive CompaniesThe University Of Texas MD Anderson Cancer Center
Active IndicationsPrimary mediastinal B cell lymphomaImmunoproliferative DisordersLymphoproliferative Disorders +[13] 
Inactive IndicationsImmune System DiseasesPrecursor Cell Lymphoblastic Leukemia-LymphomaNeoplasms

Other Information

ATC CodeL01XX
Related LinksWikipediaDrugBankKEGG